Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36793   clinical trials with a EudraCT protocol, of which   6076   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-000794-37
    Sponsor's Protocol Code Number:WO39760
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-09-04
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-000794-37
    A.3Full title of the trial
    A PHASE II, OPEN-LABEL, MULTICENTER, MULTI-COHORT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH SOLID TUMORS
    ESTUDIO DE FASE II ABIERTO, MULTICÉNTRICO Y CON VARIAS COHORTES PARA INVESTIGAR LA EFICACIA Y SEGURIDAD DE COBIMETINIB CON ATEZOLIZUMAB EN PACIENTES CON TUMORES SÓLIDOS
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Investigate the Efficacy and Safety of Cobimetinib plus Atezolizumab in Patients with Solid Tumors
    Estudio para investigar la eficacia y seguridad de Cobimetinib con Atezolizumab en pacientes con tumores sólidos
    A.4.1Sponsor's protocol code numberWO39760
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffman-La Roche Ltd.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd.
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF.Hoffmann-La Roche Ltd.
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34913257300
    B.5.6E-mailspain.start_up_unit@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCobimetinib (GDC-0973)
    D.3.2Product code RO5514041/F04
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCobimetinib (GDC-0973)
    D.3.9.1CAS number 934660-93-2
    D.3.9.2Current sponsor codeRO5514041
    D.3.9.3Other descriptive nameCOBIMETINIB, GDC-0973/XL518
    D.3.9.4EV Substance CodeSUB122319
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMPDL3280A-RO5541267
    D.3.2Product code RO5541267/F03
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNATEZOLIZUMAB
    D.3.9.2Current sponsor codeRO5541267
    D.3.9.3Other descriptive nameMPDL3280A
    D.3.9.4EV Substance CodeSUB178312
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCobimetinib (GDC-0973)
    D.3.2Product code RO5514041/F09
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCobimetinib (GDC-0973)
    D.3.9.1CAS number 934660-93-2
    D.3.9.2Current sponsor codeRO5514041
    D.3.9.3Other descriptive nameCOBIMETINIB, GDC-0973/XL518
    D.3.9.4EV Substance CodeSUB122319
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Tecentriq
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAtezolizumab
    D.3.2Product code RO5541267
    D.3.4Pharmaceutical form Concentrate and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNATEZOLIZUMAB
    D.3.9.2Current sponsor codeRO5541267
    D.3.9.4EV Substance CodeSUB178312
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Solid tumors
    Tumores sólidos
    E.1.1.1Medical condition in easily understood language
    Solid tumors are masses of abnormal tissue growth that originate in organs or soft tissues and do not include fluid areas and cysts
    Los tumores sólidos son masas de tejido de crecimiento anormal originados en órganos o téjidos blandos y no incluide en áreas líquidas y quistes
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10065252
    E.1.2Term Solid tumor
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of cobimetinib plus atezolizumab by objective response rate (ORR)
    Evaluar la eficacia de cobimetinib con atezolizumab según la Tasa de respusta Objetiva (TRO)
    E.2.2Secondary objectives of the trial
    To evaluate the efficacy of cobimetinib plus atezolizumab by OS, PFS, DOR and DCR
    To evaluate the safety of cobimetinib plus atezolizumab
    To characterize cobimetinib and atezolizumab pharmacokinetics
    To evaluate the immune response to atezolizumab
    -Evaluar la eficacia de cobimetinib con atezolizumab según Supervivencia global (SG), Supervivencia sin progresión (SSP), Duración de la respuesta (DdR) y tasa de control de la enfermedad (TCE)
    -Evaluar la seguridad de cobimetinib con atezolizumab
    -Describir la farmacocinética de cobimetinib y atezolizumab
    -Evaluar la respuesta inmunitaria a atezolizumab
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    General Inclusion Criteria:
    - Age >=18 years
    - Ability to comply with the study protocol, in the investigator's judgment
    - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
    - Life expectancy >=3 months, as determined by the investigator
    - Adequate hematologic and end-organ function
    Cancer-Related Inclusion Criteria:
    - Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST v1.1.
    - Availability to provide a representative tumor specimen biopsy. For patients with SCCHN or RCC, histologic samples are required. For patients with UC, cytological or histologic samples are acceptable.
    - Evidence of tumor progression on or after the last treatment regimen received and within 6 months prior to study enrollment
    - For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a non-hormonal contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab and within 3 months after the last dose of cobimetinib. Women must refrain from donating eggs during this same period.
    - For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm during the treatment period and for at least 3 months after the last dose of cobimetinib
    Criterios de Inclusión generales:
    - Edad >=18 años
    -Capacidad para cumplir con el protocolo del estudio a juicio del investigador
    -ECOG de 0 o 1
    - Esperanza de vida >= 3 meses según lo determinado por el investigador
    -Función hemática y del órgano afectado adecuada
    Criterios de inclusión relacionados con el cáncer:
    -Los pacientes deben presentar enfermedad cuantificable por TAC o RM conforme a los Criterios de evaluación de la respuesta en tumores sólidos (RECIST v. 1.1).
    -Disponibilidad para facilitar una biopsia tumoral representativa.En los pacientes con CECC o CCR, se necesitan muestras histológicas. En los pacientes con CU, se aceptan muestras citológicas o histológicas.
    -Indicios de progresión tumoral durante el último régimen de tratamiento recibido o después en los 6 meses anteriores a la inclusión en el estudio
    -En las mujeres en edad fértil: acceder a practicar la abstinencia (evitar las relaciones sexuales con varones) o utilizar un método anticonceptivo no hormonal con una tasa de fallos < 1 % anual durante el período de tratamiento y durante al menos 5 meses tras la última dosis de atezolizumab y 3 meses tras la última dosis de cobimetinib. Las mujeres deben abstenerse de donar óvulos durante dicho periodo
    -Para los hombres: acceder a mantener la abstinencia (evitar las relaciones heterosexuales completas) o a utilizar métodos anticonceptivos y acceder a no donar semen durante el periodo de tratamiento y en los 3 meses posteriores a la última dosis de cobimetinib
    E.4Principal exclusion criteria
    General Exclusion Criteria:
    - Inability to swallow medications
    - Malabsorption condition that would alter the absorption of orally administered medications
    - Poor peripheral venous access
    - Prior treatment with cobimetinib or a MEK inhibitor
    - For patients in Cohorts 1, 2, and 3 only: prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti−CTLA-4, anti−PD-1, and anti−PD-L1 therapeutic antibodies
    - Treatment with investigational therapy within 14 days prior to initiation of study treatment
    - Any anti-cancer therapy, including chemotherapy or hormonal therapy, within 2 weeks prior to initiation of study treatment
    - History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
    - Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, or any component of the cobimetinib formulation or hypersensitivity to any anti–PD-1/PD-L1 therapy
    - History of serous retinopathy, retinal vein occlusion (RVO), or evidence of ongoing serous retinopathy or RVO at baseline
    - Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
    - Uncontrolled tumor-related pain
    - Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days
    - Uncontrolled hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL, or corrected calcium greater than the ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
    - Active or untreated CNS metastases
    - Pregnancy or breastfeeding, or intending to become pregnant during the study
    Exclusion Criteria based on Organ Function or Medical History Cardiovascular
    Patients who meet the following cardiovascular exclusion criterion will be excluded from study entry:
    •Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or < 50%, whichever is lower Infections
    Patients who meet any of the following infection exclusion criteria will be excluded from study entry:
    •Positive HIV test at screening
    •Active hepatitis B virus (HBV) infection (chronic or acute)
    •Active hepatitis C virus (HCV) infection
    •Active tuberculosis
    •Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
    •Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
    Criterios de exclusión generales
    • Incapacidad de tragar medicamentos. Podrán permitirse otros medios de ingestión tras la obtención de la aprobación del supervisor médico.
    • Problemas de absorción que alterarían la absorción de los medicamentos administrados por vía oral
    • Mal acceso venoso periférico
    • Tratamiento anterior con cobimetinib o un inhibidor de MEK
    • En los pacientes de las cohortes 1, 2 y 3 solamente: tratamiento anterior con bloqueo de puntos de control inmunitario o coestimuladores de linfocitos T, incluidos los anticuerpos terapéuticos anti-CTLA-4, anti-PD-1 y anti-PD-L1
    • Tratamiento con fármacos experimentales en los 14 días anteriores al inicio del tratamiento del estudio
    • Cualquier tratamiento antineoplásico, incluidas la quimioterapia y la hormonoterapia, en las 2 semanas anteriores al inicio del tratamiento del estudio
    • Antecedentes de reacciones alérgicas, anafilácticas u otras reacciones de hipersensibilidad graves a anticuerpos híbridos o humanizados o proteínas de fusión
    • Hipersensibilidad conocida a los fármacos biológicos producidos en células de ovario de hámster chino, a cualquier componente de la formulación de atezolizumab ó a cualquier componente de la formulación de cobimetinib o hipersensibilidad conocida al cualquier tratamiento anti-PD-1/PD-L1
    • Antecedentes de retinopatía serosa grave, oclusión de las venas retinianas (OVR) o evidencias de retinopatía serosa en curso u OVR en el momento basal
    • Procedimiento quirúrgico importante para fines distintos al diagnóstico en las 4 semanas anteriores al inicio del tratamiento del estudio o previsión de necesitar un procedimiento quirúrgico importante durante el transcurso del estudio
    • Dolor no controlado relacionado con el tumor
    • Derrame pleural incontrolado, derrame pericárdico o ascitis que requieran procedimientos de drenaje recurrentes más de una vez cada 28 días
    • Hipercalcemia no controlada (calcio ionizado > 1,5 mmol/l, calcio > 12 mg/dl o calcio corregido superior al LSN) o hipercalcemia sintomática que requiera el uso continuado de tratamiento con bifosfonatos.
    • Metástasis en el SNC activas o sin tratar
    • Embarazo o lactancia, o intención de quedarse embarazada durante el estudio
    *Criterios de exclusión basados en la función orgánica o el historial clínico,
    Los pacientes que cumplan estos criterios cadiovasculares de exlucusión deben ser excluidos del estudio:
    • Fracción de eyección ventricular izquierda (FEVI) por debajo del límite inferior de la normalidad del centro o < 50 %, el valor que sea más bajo
    Infecciones:
    • Prueba del VIH positiva en la selección
    • Infección por virus de la hepatitis B (VHB) activa (crónica o aguda)
    • Infección por el virus de la hepatitis C (VHC) activa
    • Tuberculosis activa
    • Infección grave en las 4 semanas anteriores al inicio del tratamiento del estudio, incluidas, entre otras, la hospitalización por complicaciones de una infección, bacteriemia o neumonía grave
    • Tratamiento con antibióticos terapéuticos por vía oral o i.v. en las 2 semanas anteriores al inicio del tratamiento del estudio
    E.5 End points
    E.5.1Primary end point(s)
    1. Objective response
    1. Respuesta Objetiva
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. Up to 3 years
    1. hasta 3 años
    E.5.2Secondary end point(s)
    1. Overall survival
    2. Progression-free survival
    3. Duration of response (DOR)
    4. Disease control rate (DCR)
    5. Occurrence and severity of adverse events, with severity determined according to the NCI CTCAE v4.0
    6. Change from baseline in targeted vital signs
    7. Change from baseline in targeted clinical laboratory test results
    8. Plasma concentration of cobimetinib at specified timepoints
    9. Serum concentration of atezolizumab at specified timepoints
    10. Presence of ADAs during the study relative to the presence of ADAs at baseline
    1. SUpervivencia Global
    2. Supervivencia libre de progresión
    3. Duración de la respuesta (DdR)
    4. Tasa de control de la enfermedad (TCE)
    5. Aparición de acontecimientos adversos y su intensidad, con la intensidad determinada mediante los criterios CTCAE del NCI v4.0
    6. Alteraciones desde el momento basal en constantes vitales específicas
    7. Alteraciones desde el momento basal en resultados analíticos clínicos específicos
    8. Concentración plasmática de cobimetinib en puntos temporales específicos
    9. Concentración sérica de atezolizumab en puntos temporales específicos
    10. Presencia de AAF durante el estudio en relación con la prevalencia de AAF en el momento basal
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-7. Up to 3 years
    8. Day 15 of Cycle 3
    9-10. Day 1 (Cohorts 1-6 only), Day 15 (Cohort 7 only) of Cycle 1; Day 1 of Cycles 2, 4, 8, 12, and 16; Day 15 of Cycle 3; at atezolizumab treatment discontinuation visit, and <90 days after last atezolizumab infusion
    1-7 Hasta 3 años
    8. Día 15 de ciclo 3
    9-10 Día 1 (solo Cohortes 1-6), Día 15 (solo Cohorte 7) de Ciclo 1, Día 1 de ciclos 2,4,8,12 y 16; Día 15 de Ciclo 3; en la visita de discontinuación de Atezolizumab y <90 días después de la última infusión de atezolizumab
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA13
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Germany
    Greece
    Hungary
    Korea, Republic of
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study will end when all patients enrolled have been followed until death, withdrawal of consent, loss to follow-up, or the Sponsor decides to end the trial, whichever occurs first. Patients may continue study treatment until the development of progressive
    disease, unacceptable toxicity, and/or withdrawal of consent.
    El estudio concluirá cuando todos los pacientes incluidos hayan sido sometidos a seguimiento hasta su muerte, la revocación del consentimiento, la pérdida durante el seguimiento o la decisión del promotor de poner fin al ensayo, lo que suceda primero. Los pacientes podrán continuar con el tratamiento del estudio hasta la aparición de enfermedad progresiva, toxicidad inaceptable o la retirada del consentimiento
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 166
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 84
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 58
    F.4.2.2In the whole clinical trial 250
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Currently, the Sponsor does not have any plans to provide cobimetinib, atezolizumab or any other study treatments or interventions to patients who have completed the study. The Sponsor may evaluate whether to continue providing treatment in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, available at the following Web site: http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
    Actualmente, el Promotor no tiene palnes de porporcionar cobimetinib, Atezolizumab o cualquier otro tratamiento del estudio o intervenciones a pacientes que han completado el estudio. El promotor puede evaluar si continuar roporcionando tratamiento de acuerdo con la Política global de Roche sobre acceso continuo a productos medicinales en investigación, disponible en la siguiente web:
    http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-09-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-07-12
    P. End of Trial
    P.End of Trial StatusCompleted
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA